A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.
Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Olivia Robin McKennan(Kettering University), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Matthew D. Biniakewitz(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Sujana Movva(Memorial Sloan Kettering Cancer Center), S. Fadul Perez(Memorial Sloan Kettering Cancer Center), Haley T. Phelan(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Samuel Singer(Memorial Sloan Kettering Cancer Center), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center)
Cited by 12
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k